Vivos Therapeutics (VVOS) Equity Ratio (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Equity Ratio data on file, last reported at 0.05 in Q1 2026.

• Quarterly Equity Ratio fell 111.63% year-over-year to 0.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.05 (down 111.63% YoY) and the FY2025 annual result came in at 0.06, down 111.84% from the prior year.
• Equity Ratio climbed to 0.05 in Q1 2026 per VVOS's latest filing, from 0.06 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.71 in Q1 2022 and bottomed at 0.06 in Q4 2025.
• The 5-year median for Equity Ratio is 0.35 (2022), against an average of 0.28.
• The widest annual swing landed in 2024, when Equity Ratio surged 11101.71%; it then tumbled 111.84% in 2025.
• Tracing VVOS's Equity Ratio over 5 years: stood at 0.35 in 2022, then sank by 89.05% to 0.04 in 2023, then soared by 1258.65% to 0.52 in 2024, then plunged by 111.84% to 0.06 in 2025, then gained by 26.26% to 0.05 in 2026.
• Per Business Quant, the three latest VVOS Equity Ratio figures stand at 0.05 (Q1 2026), 0.06 (Q4 2025), and 0.1 (Q3 2025).

Peer Comparison